Article Sidebar

PDF
Date Published: 08/07/2022
Online Published: 08/07/2022
Abstract Views: 275
Views PDF: 176
DOI: https://doi.org/10.55046/vjrnm.36.605.2019
Issue
No. 36 (2019)
Section
Scientific research
How to Cite
Do, D. T., Trinh, H. C., Vu, D. L., Pham, M. T., & Ngo, L. L. (2022). Evaluate treatment results of ctace combine with intratumoral injection of cisplatin in hepatocellular carcinoma with major portal vein thrombosis. Vietnamese Journal of Radiology and Nuclear Medicine, 36, 56-61. https://doi.org/10.55046/vjrnm.36.605.2019

Evaluate treatment results of ctace combine with intratumoral injection of cisplatin in hepatocellular carcinoma with major portal vein thrombosis

Dr Do Dang Tan1, Dr Trinh Ha Chau1, Dr Vu Dang Luu1, professor Pham Minh Thong1, Dr Ngo Le Lam2
1 Radiology Center BV Bach Mai
2 Radiology Center - K Tan Trieu Hospital

Main Article Content

Abstract

Advanced stage hepatocellular carcinoma with portal vein thombosis has worse prognosis and limited treatment. Transarterial
chemoembolization use Lipiodol combined Cisplatin intratumoral is a safe method and have efficacy in treatment.
Objective: To evaluate safety and efficay of cTACE combine with intratumoral injection of Cisplatin for hepatocellular carcinoma with major portal vein shunt treatment.
Methods: From May 2018 to May 2019, 24 patients who had diagnosis of HCC with major portal vein thrombosis were perfomed cTACE (Famorubicin + Lipiodol) combined with intratumoral injection of Cisplatin. The patients were followed after treatment 1 week for the clinical symptom and after 1 month, used mRECIST and tumor markers (AFP or PIVKA-II) to aveluated treatment efficacy. The patients were perfomed consecutive courses of treatment and followed until died or until the end of study.
Results: 24 patients (21 males, 3 females), age mean is 54,4 (from 32ys to 72ys, AFP mean 15600 ng/ml (from 3 to 121000), 19
patients (79%) has size of tumor ≥5cm. The classification of portal vein thrombosis: 6 patients Vp1 and Vp2; Vp3 18 patients. Total courses of treatment was 38 times. 15 patients (62,5%) had post embolization syndrome, 8 patients (33,3%) had decreasing of tumor marker. mRECIST: CR 3 patients (12,5%); PR 6 patients (25%); SD 4 patients (16,7%); PD 11 patients (45,8%). The mean survival time was 9,9 ± 1,1 months. The survival times is depend on the classification of PVTT (p=0.037 the
mRECIST respondsibility (p=0.0001), the decreasing of tumor markers (p=0.01) and isn’t depend on the AFP before procedures.
Conclusions: cTACE combine with intratumoral injection of Cisplatin is safety an have efficacy on treatment of HCC with major
portal vein thrombosis.

Article Details

Keywords

Hepatocellular with portal vein thrombosis, cTACE, Cisplatin injection

References

1. GLOBOCAN (2012). IARC Liver Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012..
2. Llovet J.M., Bustamante J., Castells A., et al. (1999). Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 29(1), 62–67.
3. Villa E., Moles A., Ferretti I., et al. (2000). Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology, 32(2), 233–238.
4. Forner A., Llovet J.M., and Bruix J. (2012). Hepatocellular carcinoma. The Lancet, 379(9822), 1245–1255.
5. Bruix J., Sherman M., and American Association for the Study of Liver Diseases (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53(3), 1020–1022.
6. Omata M., Lesmana L.A., Tateishi R., et al. (2010). Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int, 4(2), 439–474.
7. Chung G.E., Lee J.-H., Kim H.Y., et al. (2011). Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. Radiology, 258(2), 627–634.
8. Ando E., Tanaka M., Yamashita F., et al. (2002). Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer, 95(3), 588–595.
9. Niu Z.-J., Ma Y.-L., Kang P., et al. (2012). Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Medical Oncology, 29(4), 2992–2997.
10. Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies - Journal of Vascular and Interventional Radiology. , accessed: 08/01/2019.
11. Vũ Thanh Tú (2013), Nhận xét đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị ung thư biểu mô tế bào gan giai đoạn muộn bằng sorafenid, Luận văn thạc sĩ y học, Đại học Y Hà Nội.
12. Cheng A.-L., Kang Y.-K., Chen Z., et al. (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10(1), 25–34.